Association of serum hemoglobin A1c, C‑peptide and insulin‑like growth factor‑1 levels with the occurrence and development of lung cancer

Zhang,Meiyun; Li,Xiaofeng; Zhang,Xinyi; Yang,Yongyan; Feng,Zhiqing; Liu,Xiaoyan

doi:10.3892/mco.2014.289

Association of serum hemoglobin A1c, C‑peptide and insulin‑like growth factor‑1 levels with the occurrence and development of lung cancer

Authors:
- Meiyun Zhang
- Xiaofeng Li
- Xinyi Zhang
- Yongyan Yang
- Zhiqing Feng
- Xiaoyan Liu
View Affiliations

Affiliations: Baotou Cancer Hospital, Baotou, Inner Mongolia 014030, P.R. China
Published online on: May 8, 2014 https://doi.org/10.3892/mco.2014.289
Pages: 506-508

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The present study aimed to investigate the correlation of the of hemoglobin A1c (HbA1c), C‑peptide and insulin‑like growth factor‑1 (IGF‑1) levels with the development and progression of lung cancer. The serum HbA1c, C‑peptide and IGF‑1 levels were measured and compared between 80 lung cancer patients and 80 healthy controls; furthermore, their correlation with histopathological type and tumor stage was analyzed in the 80 lung cancer patients. Our results suggested that the levels of HbA1c, C‑peptide and IGF‑1 were significantly increased in patients with lung cancer compared to those in the control group (P<0.05). In addition, the levels of C‑peptide and IGF‑1 were significantly higher in the small‑cell lung cancer group (n=18), the stage III‑IV (n=55) group and the lung cancer with diabetes mellitus group (n=43) compared to those in the non‑small‑cell lung cancer group (n=62), the stage I‑II lung cancer group (n=25) and the lung cancer without diabetes group (n=37), respectively (P<0.05). Thus, the present study suggests that the increased serum HbA1c, C‑peptide and IGF‑1 levels are significantly correlated with the development and progression of lung cancer.

View Figures

View References

1	Zhang H, Wu XK, Li B, et al: The interaction between cancer and diabetes. Chin J Gerontol. 30:3187–3188. 2010.
2	Chen HB and Chen SA: Analysis of serum glucose, insulin and and C-peptide levels in 56 liver cancer patients. Int J Lab Med. 28:496–497. 2007.
3	Fu XJ: The relationship between C-peptide and glycosylated hemoglobin in type 2 diabetes and colorectal cancer. Pract Clin Med. 10:38–39. 2009.
4	Will JC, Vinicor F and Calle EE: Is diabetes mellitus associated with prostate cancer incidence and survival? Epidemiology. 10:313–318. 1999. View Article : Google Scholar : PubMed/NCBI
5	Adami HO, McLaughlin J, Ekbom A, et al: Cancer risk in patients with diabetes mellitus. Cancer Causes Control. 2:307–314. 1991. View Article : Google Scholar : PubMed/NCBI
6	Will JC, Galuska DA, Vinicor F, et al: Colorectal cancer: another complication of diabetes mellitus? Am J Epidemiol. 147:816–825. 1998. View Article : Google Scholar : PubMed/NCBI
7	Calle EE, Murphy TK, Rodriguez C, et al: Diabetes mellitus and pancreatic cancer mortality in a prospective cohort of United States adults. Cancer Causes Control. 9:403–410. 1998. View Article : Google Scholar : PubMed/NCBI
8	Edge S, Byrd DR, Compton CC, Fritz AG, Greene FL and Trotti A: AJCC Cancer Staging Manual (Eds). 7th edition. Springer; New York: 2010
9	World Health Organization. Definition, diagnosis and classification of diabetes mellitus and its complications: Report of a WHO Consultation. Part 1. Diagnosis and classification of diabetes mellitus Geneva: World Health Organization; 1999
10	Han ST, Li XS and Chu Q: The establishment of measurement of C-peptide by chemiluminescence immunoassay. J Beihua Univ (Natural Science). 5:58–60. 2004.(In Chinese).
11	Tu GH, Jiang XG, Li L, et al: Establishment and evaluation of HPLC method for glycated hemoglobin and measurement. J Jiangsu Univ (Medical Edition). 21:147–150. 2011.
12	Liu XD and Guo XT: Explore the level of serum insulin-like growth factor-1 in patients with hypertension. J Clin Med. 16:264–265. 2007.
13	American Diabetes Association. Standards of Medical Care in Diabetes-2012. Diabetes Care. 35(Suppl 1): S11–S63. 2012. View Article : Google Scholar
14	Meiling: The tumor serum vascular endothelial growth factor and clinical significance of hemoglobin. J Clin Pract. 12:104–105. 2009.
15	Cust AE, Kaaks R, Friedenreich C, et al: Metabolic syndrome, plasma lipid, lipoprotein and glucose levels, and endometrial cancer risk in the European Prospective Investigation into Cancer and Nutrition (EPIC). Endocr Relat Cancer. 14:755–767. 2007. View Article : Google Scholar : PubMed/NCBI
16	Casa AJ, Dearth RK, Litzenburger BC, et al: The type I insulin-like growth factor receptor pathway: a key player in cancer therapeutic resistance. Front Biosci. 13:3273–3287. 2008. View Article : Google Scholar : PubMed/NCBI
17	Gunter MJ, Hoover DR, Yu H, et al: Insulin, insulin-like growth factor-I, and risk of breast cancer in postmenopausal women. J Natl Cancer Inst. 101:48–60. 2009. View Article : Google Scholar : PubMed/NCBI
18	Qian J, Dong A, Kong M, et al: Suppression of type 1 insulin-like growth factor receptor expression by small interfering RNA inhibits A549 human lung cancer cell invasion in vitro and metastasis in xenograft nude mice. Acta Biochim Biophys Sin (Shanghai). 39:137–147. 2007. View Article : Google Scholar : PubMed/NCBI